NBT-NM108 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 1 |
193. Prader-Willi syndrome
Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05541003 (ClinicalTrials.gov) | November 2022 | 1/9/2022 | Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome | Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome | Prader-Willi Syndrome;Obesity | Drug: NBT-NM108 | Rutgers, The State University of New Jersey | NULL | Recruiting | 18 Years | 35 Years | All | 10 | Phase 2 | United States |